188 related articles for article (PubMed ID: 35920701)
1. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib.
Xiao Y; Xiang H; Li W
Dermatol Ther; 2022 Oct; 35(10):e15754. PubMed ID: 35920701
[TBL] [Abstract][Full Text] [Related]
2. Possible paraneoplastic syndrome case of bullous pemphigoid with immunoglobulin G anti-BP180 C-terminal domain antibodies associated with psoriasis and primary macroglobulinemia.
Maki N; Demitsu T; Umemoto N; Nagashima K; Nakamura T; Kakurai M; Nakamura S; Yamada T; Ishii N; Hashimoto T
J Dermatol; 2016 May; 43(5):571-4. PubMed ID: 26507447
[TBL] [Abstract][Full Text] [Related]
3. Coexistence of psoriasis and bullous pemphigoid: remission with low-dose methotrexate.
Gunay U; Gunduz K; Ermertcan AT; Kandiloğlu AR
Cutan Ocul Toxicol; 2013 Jun; 32(2):168-9. PubMed ID: 22429144
[TBL] [Abstract][Full Text] [Related]
4. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature.
Li H; Wang H; Qiao G; Liu Y; Zhang F; Pan F
Int Immunopharmacol; 2023 Sep; 122():110591. PubMed ID: 37441809
[TBL] [Abstract][Full Text] [Related]
5. Bullous pemphigoid associated with psoriasis: a good response to methotrexate.
Vargas P; Giacaman P; Fernández J; Morales C
An Bras Dermatol; 2019; 94(2):224-226. PubMed ID: 31090831
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid.
Kamata M; Asano Y; Shida R; Maeda N; Yoshizaki A; Miyagaki T; Kawashima T; Tada Y; Sato S
J Dermatol; 2019 Jun; 46(6):e216-e217. PubMed ID: 30628103
[No Abstract] [Full Text] [Related]
7. A case of herpetiform pemphigus mimicking bullous pemphigoid after using secukinumab and successfully treated with sulfasalazine.
Wang R; Wang M
J Dermatol; 2023 Dec; 50(12):1625-1628. PubMed ID: 37641883
[TBL] [Abstract][Full Text] [Related]
8. Ixekizumab successfully treated refractory psoriasis concurrent bullous pemphigoid.
Xiao Y; Gu Y; Xia D; Zhou X; Li W
J Dermatol; 2023 Feb; 50(2):e76-e78. PubMed ID: 36028948
[No Abstract] [Full Text] [Related]
9. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
[TBL] [Abstract][Full Text] [Related]
10. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship?
Wilczek A; Sticherling M
Int J Dermatol; 2006 Nov; 45(11):1353-7. PubMed ID: 17076725
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
[TBL] [Abstract][Full Text] [Related]
12. Bullous Pemphigoid Masquerading as Erythrodermic Psoriasis.
De-Kaa NLP; Adefemi SA; Akuhwa RT; Fikin A; Atabo A
West Afr J Med; 2022 Dec; 39(12):1319-1323. PubMed ID: 36583972
[TBL] [Abstract][Full Text] [Related]
13. Coexistent psoriasis and bullous pemphigoid responding to mycophenolate mofetil monotherapy.
Rallis E; Anyfantakis V
Skinmed; 2008; 7(2):101-2. PubMed ID: 18327004
[TBL] [Abstract][Full Text] [Related]
14. Pemphigoid with antibodies to laminin γ1, BP180 and BP230, associated with psoriasis vulgaris: successful disease control with cyclosporin.
Imanishi A; Tateishi C; Imanishi H; Sowa-Osako J; Koga H; Tsuruta D; Hashimoto T
J Dermatol; 2015 Apr; 42(4):394-7. PubMed ID: 25708520
[TBL] [Abstract][Full Text] [Related]
15. Autoreactive Peripheral Blood T Helper Cell Responses in Bullous Pemphigoid and Elderly Patients With Pruritic Disorders.
Didona D; Scarsella L; Fehresti M; Solimani F; Juratli HA; Göbel M; Mühlenbein S; Holiangu L; Pieper J; Korff V; Schmidt T; Sitaru C; Eming R; Hertl M; Pollmann R
Front Immunol; 2021; 12():569287. PubMed ID: 33841390
[TBL] [Abstract][Full Text] [Related]
16. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
17. Anti-laminin-gamma 1 Pemphigoid with Generalized Pustular Psoriasis and Psoriasis Vulgaris.
Fujimura Y; Natsuga K; Hamade Y; Nomura Y; Kaku Y; Muramatsu R; Shimizu H
Acta Derm Venereol; 2016 Jan; 96(1):120-1. PubMed ID: 26074471
[No Abstract] [Full Text] [Related]
18. Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies.
Ständer S; Schmidt E; Zillikens D; Thaçi D; Ludwig RJ; Kridin K
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):981-987. PubMed ID: 33098720
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity.
van Beek N; Lüttmann N; Huebner F; Recke A; Karl I; Schulze FS; Zillikens D; Schmidt E
JAMA Dermatol; 2017 Jan; 153(1):30-38. PubMed ID: 27829102
[TBL] [Abstract][Full Text] [Related]
20. [Psoriasis and bullous pemphigoid].
Bork K
Hautarzt; 1987 Jun; 38(6):348-51. PubMed ID: 3308771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
